Oral Opioids for Chronic Non-cancer Pain: Higher Prevalence of Hypogonadism in Men than in Women
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The effect of chronic oral opioids on hypothalamus-pituitary-gonadal axis in women, and on bone mineral density (BMD) in men and women is not known. The objective of this cross-sectional study was to determine the effect of long-term oral opioids on gonadal status and BMD in male and female patients with chronic non-cancer pain (CNCP). We included 26 community-dwelling CNCP patients, 12 men and 14 premenopausal women, treated with oral opioids for at least one year. We obtained Visual Analogue Scale for pain score, BMD and plasma LH and FSH in all patients; menstrual history and estradiol in women; free androgen index and total and free testosterone in men. Men were older then women (p<0.05) and had used opioids for a longer period (7.2+/-3.8 and 4.1+/-1.8 years, respectively; p<0.05), but there was no difference in opioid dose or pain score between sexes. The prevalence of hypogonadism was high in men (75%), while only 21% of the women reported oligo- or amenorrhea indicating hypogonadism (P<0.01, between sexes). Osteopenia was found in 50% of men and 21% of women (p=NS). We conclude that in CNCP patients receiving chronic opioid therapy there is a much higher prevalence of hypogonadism in men then in women. This needs to be considered clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, basal TSH values have been reported to be lower (149, 153), unaffected (74, 116, 136, 155-160), or increased (118, 161).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [158]
In the citing paper
“osteopenia was detected in 50% of men and 21% of women”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [158]
In the citing paper
“suggesting a potential sexual dimorphism in long-term effects of opioids regarding gonadal status and bone health (158).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [158]
In the citing paper
“whereas only 21% of the women reported oligo-or amenorrhea indicating hypogonadism”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [158]
In the citing paper
“found high prevalence of hypogonadism in men (75%)”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [158]
Citations
Cites
Incidence of and Risk Factors for Falls and Injurious Falls among the Community-dwelling Elderly
O'Loughlin, J. L., Robitaille, Y., Boivin, J.-F., & Suissa, S. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116681 · Cited by 1,127 · cited 1×
“Attention may also be required for the increased fall frequency as reported by one-third of our patients, which is comparable to the fall frequency of 29 % found in much older community-dwelling elderly patients (O’Loughlin et al., 1993).”
ResultChronic use of opioid analgesics in non-malignant pain: Report of 38 cases
Portenoy, R. K., & Foley, K. M. (1986) · Pain · doi:10.1016/0304-3959(86)90091-6 · Cited by 897 · cited 1×
“It is estimated that about 20 % of these patients do not experience sufficient pain control with non-opioid therapy and may benefit from chronic opioid therapy (Portenoy and Foley, 1986; MacQuay, 1999).”
BackgroundCentral Nervous System–Active Medications and Risk for Falls in Older Women
Ensrud, K. E., Blackwell, T. L., Mangione, C. M., Bowman, P. J., Whooley, M. A., Bauer, D. C., Schwartz, A. V., Hanlon, J. T., Nevitt, M. C., & For The Study of Osteoporotic Fractures Research Group (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50453.x · Cited by 620
Endocrine consequences of long-term intrathecal administration of opioids
Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J.-P., Opsomer, F., Adriaensen, H., Verlooy, J., Van Havenbergh, T., Smet, M., & Van Acker, K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6615 · Cited by 491
McQuay, H. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03528-x · Cited by 414 · cited 1×
“It is estimated that about 20 % of these patients do not experience sufficient pain control with non-opioid therapy and may benefit from chronic opioid therapy (Portenoy and Foley, 1986; MacQuay, 1999).”
BackgroundHypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401 · cited 2×
“Previous studies in CNCP patients treated with intrathecal opioids have demonstrated a high prevalence of hypogonadism in both men and women (Abs et al., 2000; Finch et al., 2000), and only in men taking oral opioids (Daniell, 2002).”
ResultEvaluation of assays available to measure free testosterone
Morley, J. E., Patrick, P., & Perry, H. M. (2002) · Metabolism · doi:10.1053/meta.2002.31975 · Cited by 309 · cited 1×
“The free androgen index (FAI) was calculated by dividing total testosterone (nmol/ L) by SHBG (nmol/L), then multiplying the ratio by 100 (Morley et al., 2002, pp. 554–559).”
MethodFracture risk associated with the use of morphine and opiates
VESTERGAARD, P., REJNMARK, L., & MOSEKILDE, L. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01667.x · Cited by 244 · cited 3×
“Other population studies have found an association between opioid use and fracture rate in women and in men (Ensrud et al., 2003; Vestergaard et al., 2006), but these studies can not determine if this effect is secondary to opioid-induced hypogonadism, or due to other factors including differences…”
BackgroundBliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmüller, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0929 · Cited by 236 · cited 1×
“Recently, Bliessener et al. (Bliesener et al., 2005) reported that treatment with buprenorphine, a partial opioid receptor agonist, did not decrease testosterone levels, this in contrast to the hypogonadal effect of high dose methadone.”
BackgroundBone mineral density in subjects using central nervous system-active medications
Kinjo, M., Setoguchi, S., Schneeweiss, S., & Solomon, D. H. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.07.033 · Cited by 191 · cited 2×
“The cross sectional study by Kinjo et al. (Kinjo et al., 2005) was the first to show lower BMD scores in people receiving opioids, but no sex-specific data were presented.”
BackgroundHypogonadism in patients treated with intrathecal morphine
Finch, P. M., Roberts, L. J., Price, L., Hadlow, N. C., & Pullan, P. T. (2000) · The Clinical Journal of Pain · doi:10.1097/00002508-200009000-00011 · Cited by 144 · cited 2×
“Previous studies in CNCP patients treated with intrathecal opioids have demonstrated a high prevalence of hypogonadism in both men and women (Abs et al., 2000; Finch et al., 2000), and only in men taking oral opioids (Daniell, 2002).”
BackgroundResultOpen-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency
Daniell, H. W., Lentz, R., & Mazer, N. A. (2006) · The Journal of Pain · doi:10.1016/j.jpain.2005.10.009 · Cited by 135 · cited 1×
“A pilot study in men with opioid induced androgen deficiency found improvement of androgen deficiency symptoms, sexual function, mood, depression, and hematocrit during testosterone treatment (Daniell et al., 2006).”
BackgroundLow bone density in patients receiving methadone maintenance treatment
Kim, T. W., Alford, D. P., Malabanan, A., Holick, M. F., & Samet, J. H. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.05.027 · Cited by 131 · cited 2×
“Fourth, we did not evaluate for life-time alcohol use, which was a significant risk factor for osteopenia/osteoporosis in the study by Kim et al. (Kim et al., 2006).”
BackgroundDecreased serum testosterone concentration in male heroin and methadone addicts
Azizi, F., Vagenakis, A. G., Longcope, C., Ingbar, S. H., & Braverman, L. E. (1973) · Steroids · doi:10.1016/0039-128x(73)90002-0 · Cited by 130 · cited 1×
“For over three decades it has been known that heroin and high dose methadone maintenance therapy can decrease testosterone levels in male patients (Azizi et al., 1973).”
BackgroundOsteoporosis in Patients With Schizophrenia
Hummer, M., Malik, P., Gasser, R. W., Hofer, A., Kemmler, G., Moncayo Naveda, R. C., Rettenbacher, M. A., & Fleischhacker, W. W. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.162 · Cited by 125 · cited 1×
“A high prevalence of osteoporosis has also been found in men with depression (Mussolino et al., 2004) and schizophrenia (Hummer et al., 2005).”
BackgroundBlock, R. I., Farinpour, R., & Schlechte, J. (1991) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(91)90068-a · Cited by 112 · cited 1×
“…interact with steroid metabolism (Watanabe et al., 2005), two clinical studies did not find any effect of chronic marijuana use on plasma testosterone levels (Friedrich et al., 1990; Block et al., 1991), suggesting that the difference between men and women can not be attributed to the cannabis use.”
BackgroundOpioid-induced suppression of rat testicular function.
Adams, M. L., Sewing, B., Forman, J. B., Meyer, E. R., & Cicero, T. J. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38343-6 · Cited by 87 · cited 1×
“Animal experiments have shown that morphine, in addition to its suppressive effect on gonadotropin release, also has a direct inhibitory effect on testicular testosterone secretion that is mediated by local opioid receptors in the testes (Adams et al., 1993).”
BackgroundHormonal cut-offs of partial androgen deficiency: a survey of androgen assays.
Vermeulen, A. (2005) · PubMed · Cited by 71
Depression and Bone Mineral Density in Young Adults: Results From NHANES III
Mussolino, M. E., Jonas, B. S., & Looker, A. C. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000132873.50734.7d · Cited by 68
Marijuana extracts possess the effects like the endocrine disrupting chemicals
Watanabe, K., Motoya, E., Matsuzawa, N., Funahashi, T., Kimura, T., Matsunaga, T., Arizono, K., & Yamamoto, I. (2004) · Toxicology · doi:10.1016/j.tox.2004.08.005 · Cited by 54 · cited 1×
“While toxicology reports suggest that marijuana extracts can interact with steroid metabolism (Watanabe et al., 2005), two clinical studies did not find any effect of chronic marijuana use on plasma testosterone levels (Friedrich et al., 1990; Block et al., 1991), suggesting that the difference…”
BackgroundOsteoporosis in men: suspect secondary disease first.
Licata, A. (2003) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.70.3.247 · Cited by 25 · cited 1×
“Licata suggested that secondary causes of osteoporosis are particularly present in men (Licata, 2003).”
BackgroundGiri, M. (1994) · Endocrinology · doi:10.1210/en.135.5.2137 · Cited by 25 · cited 1×
“This effect has been attributed to opioid-mediated suppression of gonadotropin secretion, and can be prevented by administration of naloxone, an opioid-receptor antagonist (Giri and Kaufman, 1994).”
Background[Serum testosterone concentrations in cannabis and opiate users].
FRIEDRICH, G. E., Nepita, W., & André, T. (1990) · PubMed · Cited by 19
Cited by
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Self-citationDeyo, R. A., Von Korff, M., & Duhrkoop, D. (2015) · BMJ · doi:10.1136/bmj.g6380 · Cited by 507
Clinical Management of Congenital Hypogonadotropic Hypogonadism
Young, J., Xu, C., Papadakis, G. E., Acierno, J. S., Maione, L., Hietamäki, J., Raivio, T., & Pitteloud, N. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00116 · Cited by 396
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
The insults of illicit drug use on male fertility
Fronczak, C. M., Kim, E. D., & Barqawi, A. B. (2012) · Journal of Andrology · doi:10.2164/jandrol.110.011874 · Cited by 217
Metadata
- Authors
- Fraser, L.-A., Morrison, D., Morley-Forster, P., Paul, T., Tokmakejian, S., Larry Nicholson, R., Bureau, Y., Friedman, T., & Uum, S. H. M. V.
- Affiliations
- Western University (CA)
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2008-06-03
- Volume
- 117
- Issue
- 01
- Pages
- 38-43
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- PMC
- PMC2953550
- OpenAlex
- W2035484314
- Cited by
- 112
- References
- 23
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 7 · 2018: 14 · 2017: 3 · 2016: 9 · 2015: 7 · 2014: 8 · 2013: 11 · 2012: 11
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Experimental and Clinical Endocrinology & Diabetes (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u54rr014616-10)
- National Institute on Drug Abuse (R24DA017298)
- National Institute of General Medical Sciences (S06GM068510)
- National Center for Research Resources (U54-RR0 14616)
- National Institute on Minority Health and Health Disparities (S21MD000103)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD041748)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- chronic non-cancer pain, oral opioids, long-term opioid therapy, hypogonadism, hypothalamic-pituitary-gonadal axis, bone mineral density, osteopenia, sex differences, gonadotropins, testosterone, estradiol, menstrual disorders, premenopausal women
- MeSH terms
- Adolescent, Adult, Analgesics, Opioid, Female, Follicle Stimulating Hormone, Humans, Hypogonadism, Luteinizing Hormone, Male, Middle Aged, Pain, Pain Measurement, Sex Characteristics, Bone Density, Prevalence, Premenopause, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.